Comparative study of an aprepitant regimen with an ondansetron regimen, for efficacy in gynecological cancer patients with chemotherapy.
- Author:
Ji Yeung OH
1
;
Chun June LEE
Author Information
1. Department of Obstetrics and Gynecology, Gospel Hospital, Kosin University Collage of Medicine, Busan, Korea. l1000jun@naver.com
- Publication Type:Comparative Study ; Original Article
- Keywords:
Chemotherapy-induced nausea and vomiting (CINV), Aprepitant, Ondansetron
- MeSH:
Dexamethasone;
Humans;
Morpholines;
Nausea;
Ondansetron;
Prospective Studies;
Vomiting
- From:Korean Journal of Obstetrics and Gynecology
2009;52(5):538-544
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: We compared the impact of chemotherapy-induced nausea and vomiting (CINV) on patients of an aprepitant regimen with an ondansetron regimen, for antiemetic efficacy after highly emetogenic chemotherapy (HEC). METHODS: The study was performed prospective on 61 patients who is diagnosed initially the gynecological cancer during chemotherapy at Gospel hospital of Kosin university between March 2007 and October 2007. The study was divided according to an aprepitant/ondansetron regimen. The efficacy of controlling acute (during the 24 hours after chemotherapy) /delayed (day 2 days thought 5) nausea, vomiting and adverse effects were compared. Statistical analysis was performed using the chi-square test. RESULTS: The efficacy of controlling nausea with an aprepitant regimen and an ondansetron regimen was 86.7%, 83.9% in acute periods (Pvalue= 0.742) and 99%, 83.9% in delayed periods (P-value=0.083), respectively. The efficacy of controlling vomiting with an aprepitant regimen and an ondansetron regimen was 93.3%, 90.3% in acute periods (P-value=0.809) and 96.7%, 83.9% in delayed periods (Pvalue= 0.034), respectively. The efficacy of controlling delayed vomiting with an aprepitant regimen reported significantly. The common adverse effects in both groups were not significantly. CONCLUSION: The regimen including aprepitant was superior in preventing CINV as compared with a regimen in which both ondansetron and dexamethasone were given delayed periods in patients receiving chemotherapy
